Everything below concerns lipogenesis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-13. Numbers and descriptions here follow the published literature rather than marketing material.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
== Career == Yates started working out properly in 1983 at Martin's Gym in the Temple Row area of Birmingham. During this time, he won the 1984 Mr. Birmingham and became the British Heavyweight Bodybuilding Champion for the first time in 1986. His professional record consists of 15 major contest wins and two second-place finishes, and he won every contest he entered from 1992 until his retirement in 1997. His career ended in large part due to injuries such as torn biceps and triceps, the latter occurring three weeks before his final contest at the 1997 Mr. Olympia, which he nevertheless won; his victory generated controversy, with many critics and fans alike believing the runner-up Nasser El Sonbaty deserved to win. He is one of only four men to retire as a reigning Mr. Olympia. Peter McGough gave Yates the nickname "The Shadow" for his tendency to unexpectedly appear at major bodybuilding contests and win, having neither confirmed nor denied whether he would compete beforehand, and for staying out of the public eye between contests. He is considered to be the first of the "mass monsters" in bodybuilding; he combined his enormous muscle mass along with peak conditioning, quoted as being "granite hardness". He believes his career-ending injuries were due to his habit of maintaining an extreme level of training intensity all year long, even when approaching contests and while cutting weight.
The two substrates of this enzyme are 5,10-methylenetetrahydrofolate and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are 5,10-methenyltetrahydrofolate, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-NH group of donors with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 5,10-methylenetetrahydrofolate:NAD+ oxidoreductase. This enzyme is also called methylenetetrahydrofolate dehydrogenase (NAD+). This enzyme participates in one carbon pool by folate.
== Research == Due to its accumulation in airway epithelial cells in various respiratory diseases, such as COVID-19, cystic fibrosis, influenza, and sepsis, hyaluronic acid is under study as a possible mediator of lung inflammatory mechanisms, as of 2022. The high biocompatibility of hyaluronic acid and its common presence in the extracellular matrix of tissues indicate its possible use as a biomaterial scaffold in tissue engineering. In particular, research groups have found hyaluronan's properties for tissue engineering and regenerative medicine may be improved with cross-linking, producing a hydrogel. Crosslinking may allow a desired shape, as well as to deliver therapeutic molecules into a host. Hyaluronan can be crosslinked by attaching thiols (see thiomers) (trade names: Extracel, HyStem), hexadecylamides (trade name: Hymovis), and tyramines (trade name: Corgel). Hyaluronan can also be crosslinked directly with formaldehyde (trade name: Hylan-A) or with divinylsulfone (trade name: Hylan-B). Hyaluronic acid can also be crosslinked with a bifunctional crosslinking agent 1,4-Butanediol diglycidyl ether (BDDE) using a ResonantAcoustic mixer over a period of time ranging from about 1 minute to about 10 minutes. Due to its ability to regulate angiogenesis by stimulating endothelial cells to proliferate in vitro, hyaluronan can be used to create hydrogels to study vascular morphogenesis. Research shows that abnormal hyaluronic acid (HA) metabolism is a major factor in tumor progression.
Biodistribution of 14C-labelled docetaxel in three patients showed the bulk of the drug to be metabolised and excreted in bile to the faeces. Of the radioactively labelled docetaxel administered, 80% was eliminated to the faeces with 5% in the urine over seven days, an indication that urinary excretion of docetaxel is minimal. Saliva contributed minimal excretion and no excretion was detected through pulmonary means. The terminal half-life of docetaxel was determined as approximately 86 hours, through prolonged plasma sampling, contrary to the clinically stated terminal half-life of 10–18 hours.
Brinckerhoff (1922), former CEO and chairman of Anaconda Copper, world's largest producer of copper Morris Schapiro (1923), investment banker, grandfather of painter Jacob Collins '86 and brother of art historian Meyer Schapiro '24 Lawrence Wien (1925), real estate magnate and philanthropist who owns the Empire State Building Francis Levien (1926), lawyer, director of Gulf and Western Industries, namesake of Levien Gymnasium Herbert Hutner (1928), private investment banker, attorney, and philanthropist; fourth husband of socialite Zsa Zsa Gabor Ivan Veit (1928), former executive vice president of The New York Times Nathan S. Ancell (1929), co-founder of furniture company Ethan Allen Ira D. Wallach (1929), head of Central National-Gottesman, the largest privately held marketer of paper and pulp products Benedict I. Lubell (1930), oilman, philanthropist Arthur Ross (1931), philanthropist, businessman; vice president of Central National-Gottesman; namesake of Arthur Ross Pinetum in Central Park Henry G. Walter Jr. (1931), businessman, former chairman and CEO of International Flavors & Fragrances and pioneer in aromatherapy Robert D. Lilley (1933), former president of AT&T 1972–1976 and the New Jersey Bell Telephone Company 1965–1970 Macrae Sykes (1933), investment banker, former chairman of the American Stock Exchange Robert David Lion Gardiner (1934), banker, landowner, 16th Lord of the manor of Gardiners Island, direct descendant of 17th-century English settler Lion Gardiner Arnold A. Saltzman (1936), businessman, diplomat, art collector, philanthropist George J.
Sources: en.wikipedia.org
Size of wound: Should be accurately measured at time of initial presentation and regularly remeasured until wound resolution. Wound location: Very useful consideration in many chronic wounds, such as diabetic foot ulcers, pressure ulcers, and venous ulcers. Acute wounds will be located in areas consistent with the mechanism of injury (e.g. diagonal chest wall bruising from seatbelt following car accident). Wound bed: A healthy wound bed will appear pink due to healthy granulation tissue. Presence of a dark red wound bed which bleeds easily on contact or excess granulation tissue (i.e. hypergranulation tissue) may indicate the presence of an infection or non-healing wound. Wound depth: The depth of a wound is often not apparent on visual inspection alone. Proper evaluation of wound depth includes use of a probe to measure wound depth and evaluate for undermining of wound edges or sinus/fistula formation. Necrotic tissue, slough, eschar: Wounds may be covered with a layer of dead tissue which may appear cream/yellow in color (slough) or as a black, hardened tissue (eschar). Removing this tissue is critical for properly evaluating both the depth of a wound and quality of the wound bed, and promotes wound healing. Wound edges: May provide clues to cause of specific wounds, such as gently sloping edges of venous ulcers or rolled edges of certain tumors.
== Medical uses == Alendronatec sodium is indicated for the treatment and prevention of osteoporosis in postmenopausal women; the treatment to increase bone mass in men with osteoporosis; the treatment of glucocorticoid-induced osteoporosis; and the treatment of Paget's disease of bone.
Normative ESC values have also been established for pediatric age groups, and it has been demonstrated that ESC values begin to decrease in the eighth decade of life. ESC has the potential to be a useful tool for detecting small fiber neuropathies. It is highly sensitive, rapid, more accessible and less technically complex than current gold standard sudomotor function tests, and causes minimal-to-no patient discomfort, so very suitable for routine use.
After entering the body, aflatoxins may be metabolized by the liver to a reactive epoxide intermediate or hydroxylated to become the less harmful aflatoxin M1. Aflatoxin poisoning most commonly results from ingestion, but the most toxic aflatoxin compound, B1, can permeate through the skin. The United States Food and Drug Administration (FDA) action levels for aflatoxin present in food or feed is 20 to 300 ppb. The FDA has had occasion to declare both human and pet food recalls as a precautionary measure to prevent exposure. The term "aflatoxin" is derived from the name of the species Aspergillus flavus, in which some of the compounds were first discovered. A new disease was identified with unknown characteristics in England during the 1950s and 1960s, which increased turkey mortality. Later, aflatoxin was recognized in 1960 in England as a causative agent of the mysterious Turkey X disease that causes excessive mortality in turkey poults. Aflatoxins form one of the major groupings of mycotoxins.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.